Bee Vectoring Technologies International

Overview
News
Biopesticides?
Product stageSegments
Go-to-Market
?
Biotic agents
?

Bee Vectoring Technologies International Inc. (BVT) is an agriculture technology company that has pioneered a natural precision agriculture system to replace chemical pesticides. BVT's patented technology, precision vectoring, utilizes commercially grown bees to deliver biological pesticide alternatives directly to crops. By allowing minute amounts of naturally-derived pesticides (biologicals) to be delivered directly to blooms, it provides improved crop protection and yield results compared to traditional chemical pesticides.

BVT's proprietary biological control agent, Clonostachys rosea strain CR-7 (CR-7), has demonstrated promising results through global field trials and early commercialization phases. In January 2023, BVT signed a commercial agreement with BioSafe Systems, an industry leader in sustainable products, to offer a range of CR-7-based products for foliar and soil drench markets in the US. This agreement enables BVT to expand its product reach beyond bee vectoring into the larger foliar and soil-applied crop protection market.

In February 2024, BVT announced that its precision agriculture system commenced trials in greenhouse tomato crops in Spain with Agrobeío SL, a leading producer of beneficial insects. This trial is part of the EU-funded ADOPT-IPM project, aimed at optimizing Integrated Pest Management (IPM) tools and fostering stakeholder adoption.

BVT currently holds over 55 granted patents and has obtained US EPA registration of its Vectorite with CR-7 (EPA Registration No. 90641-2) as a registered biological fungicide for labeled crops.


Sources

Disclaimer: This company profile has been generated using data obtained through automated web searches and advanced generative AI technology. While we strive to ensure the accuracy and reliability of our sources, auto-generated information could be outdated or inaccurate and should be verified independently.
HQ location:
#7 – 4160 Sladeview Crescent Sladeview Crescent Mississauga ON CAN
Founded year:
2011
Employees:
251-500
IPO status:
Public
Total funding:
USD 15.8 mn
Last Funding:
USD 736.4 k (Post IPO Debt; Dec 2023)
Last valuation:
-
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.